OncoPharm Polatuzumab-vedotin
6 snips
Jun 13, 2019 Dive into the world of cutting-edge cancer treatment with a focus on a newly approved drug for relapsed/refractory diffuse large B-cell lymphoma. Discover the mechanisms behind polatuzumab-vedotin and why it’s considered a game-changer. Hear about its efficacy and safety profiles compared to traditional therapies. Learn the precautions necessary for administration and the promising results that have emerged from clinical trials. This discussion is a must-listen for anyone interested in oncology advancements!
AI Snips
Chapters
Transcript
Episode notes
Mechanism and Administration of Polatuzumab-Vedotin
- Polatuzumab-vedotin targets CD79B on B-cells and delivers MMAE, a microtubule poison, causing cell death.
- It requires infusion with premedication and observation due to risk of infusion reactions.
Key Toxicities of Polatuzumab
- Peripheral neuropathy occurs in about 40% of patients, mostly sensory and cumulative, with few severe cases.
- Infusion reactions can occur during or up to 24 hours post-infusion, requiring monitoring beyond administration.
Infection Risks and Prophylaxis
- Despite relatively low neutropenia, there is increased pneumonia risk, so prophylaxis for herpes and PJP is recommended.
- GCSF may be administered to reduce febrile neutropenia risk, especially in older patients.